CFTR and infection: While some CFTR modulators reduce the number of pulmonary exacerbations and of patients requiring i.v. antibiotic prescription in the short term (25, 26), other studies indicate that bacterial titer and concentrations of inflammatory mediators in the airways remain elevated in patients even after prolonged treatment with modulators (27–29), indicating that the impact of these therapies on lung inflammation and infection is unclear.